Cytek Biosciences (CTKB) Stock Forecast, Price Target & Predictions
CTKB Stock Forecast
Cytek Biosciences stock forecast is as follows: an average price target of $8.50 (represents a 25.37% upside from CTKB’s last price of $6.78) and a rating consensus of 'Buy', based on 4 wall street analysts offering a 1-year stock forecast.
CTKB Price Target
The average price target for Cytek Biosciences (CTKB) is $8.50 based on 1-year price targets from 4 Wall Street analysts in the past 3 months, with a price target range of $8.50 to $8.50. This represents a potential 25.37% upside from CTKB's last price of $6.78.
CTKB Analyst Ratings
According to 4 Wall Street analysts, Cytek Biosciences's rating consensus is 'Buy'. The analyst rating breakdown for CTKB stock is 0 'Strong Buy' (0.00%), 3 'Buy' (75.00%), 1 'Hold' (25.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Cytek Biosciences Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| May 13, 2024 | Dave Westenberg | Piper Sandler | $8.50 | $6.15 | 38.21% | 25.37% |
| Aug 17, 2022 | David Westenberg | Piper Sandler | $16.00 | $14.08 | 13.64% | 135.99% |
| May 15, 2022 | David Westenberg | Piper Sandler | $12.00 | $9.38 | 27.93% | 76.99% |
The latest Cytek Biosciences stock forecast, released on May 13, 2024 by Dave Westenberg from Piper Sandler, set a price target of $8.50, which represents a 38.21% increase from the stock price at the time of the forecast ($6.15), and a 25.37% increase from CTKB last price ($6.78).
Cytek Biosciences Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | 1 |
| Avg Price Target | - | - | $8.50 |
| Last Closing Price | $6.78 | $6.78 | $6.78 |
| Upside/Downside | -100.00% | -100.00% | 25.37% |
In the current month, the average price target of Cytek Biosciences stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Cytek Biosciences's last price of $6.78. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| May 13, 2024 | Piper Sandler | Overweight | Overweight | Hold |
| Dec 14, 2023 | Stephens | - | Positive | Initialise |
| Oct 24, 2023 | Morgan Stanley | Equal-Weight | Equal-Weight | Hold |
| Aug 17, 2022 | Piper Sandler | Overweight | Overweight | Hold |
| Jul 19, 2022 | Piper Sandler | Overweight | Overweight | Hold |
| May 15, 2022 | Piper Sandler | Overweight | Overweight | Hold |
| May 12, 2022 | Goldman Sachs | Buy | Buy | Hold |
Cytek Biosciences's last stock rating was published by Piper Sandler on May 13, 2024. The company gave CTKB a "Overweight" rating, the same as its previous rate.
Cytek Biosciences Financial Forecast
Cytek Biosciences Revenue Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | $58.60M | $48.00M | $49.69M | $37.09M | $48.34M | $40.48M | $40.16M | $35.06M | $38.89M | $34.38M | $30.41M |
| Avg Forecast | $81.17M | $65.77M | $61.28M | $57.41M | $69.59M | $58.09M | $54.67M | $49.66M | $61.49M | $50.70M | $49.53M | $43.59M | $56.58M | $55.48M | $45.71M | $47.15M | $50.22M | $43.29M | $39.63M | $32.51M | $36.42M | $33.37M | $28.27M |
| High Forecast | $83.00M | $67.26M | $62.66M | $58.71M | $71.16M | $59.40M | $55.90M | $50.33M | $62.71M | $51.49M | $50.65M | $44.57M | $57.86M | $55.48M | $46.75M | $48.21M | $51.36M | $43.29M | $39.63M | $32.51M | $36.42M | $33.37M | $28.27M |
| Low Forecast | $78.77M | $63.83M | $59.46M | $55.72M | $67.53M | $56.37M | $53.05M | $48.85M | $60.12M | $49.90M | $48.06M | $42.30M | $54.91M | $55.48M | $44.36M | $45.75M | $48.74M | $43.29M | $39.63M | $32.51M | $36.42M | $33.37M | $28.27M |
| # Analysts | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 4 | 4 | 2 | 1 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 1.04% | 0.87% | 1.09% | 0.79% | 0.96% | 0.94% | 1.01% | 1.08% | 1.07% | 1.03% | 1.08% |
Cytek Biosciences's average Quarter revenue forecast for Mar 24 based on 1 analysts is $43.59M, with a low forecast of $42.30M, and a high forecast of $44.57M. CTKB's average Quarter revenue forecast represents a -25.62% decrease compared to the company's last Quarter revenue of $58.60M (Dec 23).
Cytek Biosciences EBITDA Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 4 | 4 | 2 | 1 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | $3.32M | $-3.59M | $-9.13M | $-8.37M | $4.80M | $3.27M | $800.00K | $-1.24M | $936.00K | $2.71M | $3.90M |
| Avg Forecast | $3.73M | $3.03M | $2.82M | $2.64M | $3.20M | $2.67M | $2.51M | $2.28M | $2.83M | $2.33M | $2.28M | $2.01M | $2.60M | $2.55M | $2.10M | $2.17M | $2.31M | $1.99M | $1.82M | $1.50M | $1.68M | $1.54M | $1.30M |
| High Forecast | $3.82M | $3.09M | $2.88M | $2.70M | $3.27M | $2.73M | $2.57M | $2.32M | $2.88M | $2.37M | $2.33M | $2.05M | $2.66M | $2.55M | $2.15M | $2.22M | $2.36M | $1.99M | $1.82M | $1.50M | $1.68M | $1.54M | $1.30M |
| Low Forecast | $3.62M | $2.94M | $2.74M | $2.56M | $3.11M | $2.59M | $2.44M | $2.25M | $2.77M | $2.30M | $2.21M | $1.95M | $2.53M | $2.55M | $2.04M | $2.10M | $2.24M | $1.99M | $1.82M | $1.50M | $1.68M | $1.54M | $1.30M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 1.28% | -1.41% | -4.34% | -3.86% | 2.08% | 1.64% | 0.44% | -0.83% | 0.56% | 1.76% | 3.00% |
1 analysts predict CTKB's average Quarter EBITDA for Mar 24 to be $2.01M, with a high of $2.05M and a low of $1.95M. This is -39.66% lower than Cytek Biosciences's previous annual EBITDA (Dec 23) of $3.32M.
Cytek Biosciences Net Income Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 4 | 4 | 2 | 1 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | $6.30M | $-6.46M | $-4.39M | $-6.81M | $3.53M | $1.67M | $-702.00K | $-2.16M | $-1.17M | $1.42M | $2.67M |
| Avg Forecast | $11.95M | $4.65M | $663.93K | $-1.33M | $15.05M | $6.97M | $7.08M | $3.54M | $14.16M | $1.53M | $-380.70K | $-3.32M | $3.98M | $2.92M | $1.59M | $2.99M | $5.64M | $1.64M | $1.64M | $-1.31M | $3.29M | $3.07M | $1.31M |
| High Forecast | $12.30M | $4.78M | $683.43K | $-1.28M | $15.49M | $7.18M | $7.29M | $5.90M | $19.83M | $1.58M | $-366.06K | $-3.19M | $4.10M | $3.01M | $1.64M | $3.08M | $5.81M | $1.64M | $1.64M | $-1.31M | $3.29M | $3.07M | $1.31M |
| Low Forecast | $11.49M | $4.47M | $638.41K | $-1.37M | $14.47M | $6.70M | $6.81M | $2.36M | $11.33M | $1.47M | $-391.88K | $-3.42M | $2.66M | $2.81M | $1.53M | $2.87M | $5.43M | $1.64M | $1.64M | $-1.31M | $3.29M | $3.07M | $1.31M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 1.58% | -2.21% | -2.75% | -2.28% | 0.63% | 1.01% | -0.43% | 1.64% | -0.35% | 0.46% | 2.03% |
Cytek Biosciences's average Quarter net income forecast for Mar 24 is $-3.32M, with a range of $-3.42M to $-3.19M. CTKB's average Quarter net income forecast represents a -152.69% decrease compared to the company's last Quarter net income of $6.30M (Dec 23).
Cytek Biosciences SG&A Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 4 | 4 | 2 | 1 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | - | $21.90M | $22.43M | $25.15M | $23.23M | $19.54M | $16.85M | $17.02M | $14.51M | $15.24M | $12.30M | $9.74M |
| Avg Forecast | $29.23M | $23.68M | $22.06M | $20.67M | $25.06M | $20.92M | $19.68M | $17.88M | $22.14M | $18.25M | $17.83M | $15.69M | $20.37M | $19.97M | $16.46M | $16.98M | $18.08M | $15.59M | $14.27M | $11.71M | $13.11M | $12.02M | $10.18M |
| High Forecast | $29.89M | $24.22M | $22.56M | $21.14M | $25.62M | $21.39M | $20.13M | $18.12M | $22.58M | $18.54M | $18.24M | $16.05M | $20.83M | $19.98M | $16.83M | $17.36M | $18.49M | $15.59M | $14.27M | $11.71M | $13.11M | $12.02M | $10.18M |
| Low Forecast | $28.36M | $22.98M | $21.41M | $20.06M | $24.32M | $20.30M | $19.10M | $17.59M | $21.65M | $17.97M | $17.31M | $15.23M | $19.77M | $19.97M | $15.97M | $16.47M | $17.55M | $15.59M | $14.27M | $11.71M | $13.11M | $12.02M | $10.18M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 1.07% | 1.12% | 1.53% | 1.37% | 1.08% | 1.08% | 1.19% | 1.24% | 1.16% | 1.02% | 0.96% |
Cytek Biosciences's average Quarter SG&A projection for Mar 24 is $15.69M, based on 1 Wall Street analysts, with a range of $15.23M to $16.05M. The forecast indicates a -28.34% fall compared to CTKB last annual SG&A of $21.90M (Dec 23).
Cytek Biosciences EPS Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 4 | 4 | 2 | 1 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | $0.05 | $-0.05 | $-0.03 | $-0.05 | $0.03 | $0.01 | $-0.01 | $-0.02 | $-0.01 | - | $0.02 |
| Avg Forecast | $0.09 | $0.04 | $0.01 | $-0.01 | $0.11 | $0.05 | $0.05 | $0.03 | $0.11 | $0.01 | $-0.00 | $-0.03 | $0.03 | $0.02 | $0.01 | $0.02 | $0.04 | $0.01 | $0.01 | $-0.01 | $0.03 | $0.02 | $0.01 |
| High Forecast | $0.09 | $0.04 | $0.01 | $-0.01 | $0.12 | $0.05 | $0.05 | $0.04 | $0.15 | $0.01 | $-0.00 | $-0.02 | $0.03 | $0.02 | $0.01 | $0.02 | $0.04 | $0.01 | $0.01 | $-0.01 | $0.03 | $0.02 | $0.01 |
| Low Forecast | $0.09 | $0.03 | - | $-0.01 | $0.11 | $0.05 | $0.05 | $0.02 | $0.09 | $0.01 | $-0.00 | $-0.03 | $0.02 | $0.02 | $0.01 | $0.02 | $0.04 | $0.01 | $0.01 | $-0.01 | $0.03 | $0.02 | $0.01 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 1.61% | -2.15% | -2.69% | -2.23% | 0.61% | 0.80% | -0.42% | 1.61% | -0.43% | 0.19% | 2.04% |
According to 1 Wall Street analysts, Cytek Biosciences's projected average Quarter EPS for Mar 24 is $-0.03, with a low estimate of $-0.03 and a high estimate of $-0.02. This represents a -151.87% decrease compared to CTKB previous annual EPS of $0.05 (Dec 23).
Cytek Biosciences Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| VAPO | Vapotherm | $2.17 | $128.00 | 5798.62% | Hold |
| APYX | Apyx Medical | $1.34 | $8.50 | 534.33% | Buy |
| INGN | Inogen | $10.33 | $26.00 | 151.69% | Buy |
| SGHT | Sight Sciences | $3.98 | $9.00 | 126.13% | Hold |
| LUNG | Pulmonx | $6.72 | $11.93 | 77.53% | Buy |
| KIDS | OrthoPediatrics | $24.26 | $39.60 | 63.23% | Buy |
| RXST | RxSight | $44.65 | $70.11 | 57.02% | Buy |
| NPCE | NeuroPace | $9.15 | $12.88 | 40.77% | Buy |
| LIVN | LivaNova | $53.58 | $70.50 | 31.58% | Buy |
| OFIX | Orthofix Medical | $18.64 | $24.00 | 28.76% | - |
| CTKB | Cytek Biosciences | $6.78 | $8.50 | 25.37% | Buy |
| SRDX | Surmodics | $38.17 | $39.50 | 3.48% | Buy |